Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
T2DM is a metabolic disorder characterized by long-term hyperglycemia and is one of the leading causes of morbidity and mortality
GLP-1-based therapy for obesity
Presented for research literature review only Chen H et al
Coverage depends on whether the medication is prescribed for medical reasons, such as obesity or weight-related health conditions
In the STEP-4 trial, 902 participants received semaglutide 2.4 mg for the initial 20 weeks, and were then randomly assigned to receive either (a) semaglutide or (b) a placebo for the remaining 48 weeks (4)
At Metropolis Healthcare, we understand the importance of personalised care in managing conditions like type 2 diabetes and obesity
US$ 29.37
US$ 22.30
US$ 27.43
US$ 28.24
US$ 24.96
US$ 20.92
US$ 22.06
